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MaBACKGROUND Renal denervation is a new interventional approach to treat hypertension with variable results.
OBJECTIVES The purpose of this study was to correlate response to endovascular radiofrequency ablation of renal
arteries with nerve and ganglia distributions. We examined how renal neural network anatomy affected treatment efﬁcacy.
METHODS A multielectrode radiofrequency catheter (15 W/60 s) treated 8 renal arteries (group 1). Arteries and kidneys
were harvested 7 days post-treatment. Renal norepinephrine (NEPI) levels were correlated with ablation zone geometries
and neural injury. Nerve and ganglion distributions and sizes were quantiﬁed at discrete distances from the aorta and
were compared with 16 control arteries (group 2).
RESULTS Nerve and ganglia distributions varied with distance from the aorta (p < 0.001). A total of 75% of nerves fell
within a circumferential area of 9.3, 6.3, and 3.4 mm of the lumen and 0.3, 3.0, and 6.0 mm from the aorta. Efﬁcacy
(NEPI 37 ng/g) was observed in only 1 of 8 treated arteries where ablation involved all 4 quadrants, reached a depth of
9.1mm, and affected 50%of nerves. In 7 treated arteries, NEPI levels remained at baseline values (620 to 991 ng/g),#20%
of the nerves were affected, and the ablation areas were smaller (16.2  10.9 mm2) and present in only 1 to 2 quadrants
at maximal depths of 3.8  2.7 mm.
CONCLUSIONS Renal denervation procedures that do not account for asymmetries in renal periarterial nerve and
ganglia distribution may miss targets and fall below the critical threshold for effect. This phenomenon is most acute in
the ostium but holds throughout the renal artery, which requires further deﬁnition. (J Am Coll Cardiol 2014;64:1079–87)
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NEPI = norepinephrine
RA = renal artery
RDN = renal denervation
RF = radiofrequency
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1080empirically, as there is no intraprocedural
test available to assess sufﬁcient wall contact
or effective destruction of renal nerves (8).
RDN was recommended to commence
distally and to be withdrawn by pulling and
rotating the catheter tip, and it involved at
least 4 focal treatments with a distance
of $5 mm between each site (9).SEE PAGE 1088As the superior aspect of the RA is thought to be
especially rich in ganglia and sympathetic nerves, it is
recommended to apply the last ablations close to the
ostium in a superior position (10). However, ganglia
distributions along the RA have not been published,
and published nerve mapping (11–13) has relied on
coarse segmentation of the RA into proximal, middle,
and distal segments that provides little insight into
ostial anatomy. We, therefore, performed a similar
procedure in Yorkshire swine, quantiﬁed the varia-
tion of nerve and ganglion size and density with
distance from the aorta, and correlated these
anatomical features with RF ablation efﬁcacy.
METHODS
ANIMAL MODELS AND EXPERIMENTAL OVERVIEW. All
animal experiments were performed at CBSET, Inc.
(Lexington, Massachusetts) and adhered to the Guide
for the Care and Use of Laboratory Animals (14) under
an institutional animal care and use committee-
approved protocol. In total, 24 renal arteries from
12 castrated male Yorkshire swine (age 4.5 to 5.0
months) were assessed.
Group 1 consisted of 4 pigs (41.3 to 44.6 kg)
undergoing bilateral denervation of the aorta/renalrmation of Electrode Positions Relative to the Ostium
ectrodes utilized for 2-electrode treatment (A) andartery with a prototype multielectrode renal crescent
catheter (Biosense Webster, Diamond Bar, California)
using a custom-designed generator that indepen-
dently controlled the power of each monopolar elec-
trode and the irrigation rate of room temperature
saline (w23C) through electrode ports. To reduce
variability in energy delivery by the monopolar elec-
trodes, ground pads were placed at the same position
(between the shoulder blades) in each treated animal.
Each treatment was administered under ﬂuoroscopic
guidance by up to 3 electrodes (15 W/30 s): 1 at the
aortic inlet of the ostium and up to 2 neighboring
electrodes deeper within the ostium (Figure 1). Elec-
trode dimensions (3 mm) and spacing (4 mm) along
with catheter curvature ensured that treatment sites
did not extend beyond w6 mm from the aorta. Ani-
mals were euthanized on day 7, and renal arteries
and associated aorta were removed en bloc, preser-
ving orientation and surrounding tissue. Kidney
samples were collected, ﬂash frozen, and shipped
for norepinephrine (NEPI) analysis. RA sections at
3 predetermined distances from the aorta were
analyzed morphometrically to determine ablation
area dimensions and quantify the diameters and
locations of nerves and ganglia as detailed in the
following text.
Group 2 consisted of 8 pigs (52.1 to 63.2 kg) that did
not undergo ostial RDN but were used to analyze
nerve and ganglia size and positional distribution at
the same 3 distances from the aorta.
HISTOLOGY OF RAS. Each RA with surrounding
tissue was trimmed at intervals of 3 to 5 mm to yield
3 cross sections at the aortic ostium. Anatomic
orientation was preserved through tissue harvest and
processing (e.g., via inking, tagging, and standardi-
zation of embedding and slide generation). One
hematoxylin and eosin–stained slide and 1 elastin
Masson’s trichrome–stained slide were generated per
parafﬁn-embedded section. Immunohistochemical
staining for tyrosine hydroxylase and for calcitonin
gene-related peptide was performed on a subset of
sections. To evaluate for any treatment effects at the
aortic ostium of the RAs, a series of 5 sagittal aortic
sections was similarly stained and evaluated.
HISTOPATHOLOGY EVALUATION AND NERVE
ASSESSMENT OF TREATED ARTERIES. A board-
certiﬁed veterinary pathologist, using light micro-
scopy, examined the histologic sections of the renal
arteries and associated tissue. Tissue ablation, as
deﬁned by localized coagulative or necrotic changes,
was scored qualitatively, and also quantiﬁed using
Olympus MicroSuite Biological Suite (Olympus, Cen-
ter Valley, Pennsylvania). Metrics quantiﬁed included
TABLE 1 Effects 7 Days Post-Treatment Ordered According to Increasing NEPI Values
Artery
No. of Treating
Electrodes
NEPI,
ng/g
Affected
Nerves, %*
Maximal
Depth, mm
Maximal
Width, mm
Maximal
Area, mm2
1 2† 37.0 63.6% 9.05 15.92 99.09
2 1 619.9 9.1% 3.68 6.62 13.02
3 2 756.1 0.0% 1.85 11.59 14.14
4 2 822.5 20.0% 1.61 2.73 2.35
5 2 893.1 0.0% 7.13 5.69 19.53
6 2 931.8 19.1% 1.74 4.59 7.06
7 3 954.5 16.7% 7.96 7.31 35.80
8 2‡ 990.7 8.3% 2.55 9.70 21.64
*Average (SDs) evaluated over sections with evidence of treatment. †Ostial electrode power ¼ 8.0 W. ‡Ostial
electrode power ¼ 7.6 W.
NEPI ¼ norepinephrine.
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1081total treatment area, width, and depth (deﬁned rela-
tive to the wall/lumen interface). Nerves and ganglia
were counted on a quadrant basis, their status with
regard to treatment zone was determined, and
any nerve changes were characterized as primarily
degenerative, necrotic, or chronic/reactive. For each
treated RA, the percentages of affected nerves and
ganglia were calculated in sections showing evidence
of mural treatment.
NERVE AND GANGLION DISTRIBUTIONS. Close to
the ostium, there is a splay between the neural plexus
and artery that normalizes beyond, and in the distal
segment there is a tapering of the vessel. This
allowed us to evaluate treatment effects at 3 dis-
tances from the aortic ostium (w0.3, w3.0, and w6.0
mm) where nerve and ganglia distribution and RA
diameter differ. We deﬁned nerve and ganglia loca-
tions by their distance from the luminal surface and
angle relative to an estimated center of the lumen.
Sizes were deﬁned by the largest in-plane diameter.
Illustrative maps of nerve and ganglia distributions
were generated after shifting each of the individual
depths by a representative RA lumen radius of
2.5 mm. As both left and right arteries contributed to
the composite map, the orientation of right arterial
structures was shifted by 180 to maintain consistent
orientation. Maps included overlays of traced abla-
tion areas (also shifted by a representative lumen
radius of 2.5 mm). Aortic ostial sections were similarly
evaluated, but no nerve treatment effects were
present.
KIDNEY BIOANALYSIS (NEPI) AND CORRELATION
WITH NERVE EFFECTS. Following euthanasia, kid-
neys were rapidly harvested and minced on dry ice.
Kidneys were homogenized and duplicate aliquots
were analyzed for quantiﬁcation of NEPI content by
a high-performance liquid chromatography-mass
spectrometry assay using stable isotope-labeled ana-
lytes as previously described (15,16). NEPI levels were
reported as ng/g renal tissue. The observed mono-
tonic dependence of NEPI on the average percentage
of affected nerves (X) was ﬁt to a logistic form:
NEPI ¼ NEPImin þ
NEPImax  NEPImin
1 þ e
X  X50
Slope
[1]
Here, NEPImax is the maximal control NEPI concen-
tration, NEPImin is the minimal achievable NEPI
concentration, X50 denotes the percentage of
affected nerves that ensure a half-maximal reduc-
tion in NEPI, and the value of slope determines the
sharpness of the decline.
STATISTICAL ANALYSIS. Experimental values are
reported descriptively as mean  SD. The data ﬁt toEquation 1 was performed using GraphPad Prism 3.01
(GraphPad Software, San Diego, California). Contin-
uous (i.e., radial distance, angle, and size) and
discrete (i.e., abundance) nerve/ganglion data were
pooled from all vessels and categorized by their dis-
tance from the aorta. Pairwise and multiple compar-
isons were conducted based on data categorization.
For all statistical tests, datasets were ﬁrst assessed for
normality using a Shapiro-Wilk test (SigmaPlot 11.0,
Systat Software, San Jose, California). For pairwise
comparisons, if normality was met, a Student t test
was conducted; otherwise, a Mann-Whitney rank sum
test was performed. For multiple comparisons, if
normality was met, a 1-way analysis of variance,
Holm Sidak test was performed; otherwise a Kruskal-
Wallis 1-way analysis of variance on Ranks, Dunn’s
test was performed. For all statistical tests, the null
hypothesis of no difference was only rejected if the
value of the calculated statistic was <0.05 (p < 0.05).
RESULTS
PORCINE TREATMENT EFFECTS. Maximal zones of
injury were achieved at the RA sections closest to the
aorta for all treatments. Maximal ablation zones var-
ied in orientation and shape, and often included or
bordered anatomic structures, such as lymph nodes,
other large blood vessels, and the hypaxial skeletal
muscle. Quantitative morphometry of maximal abla-
tion zones (Table 1) estimated depth (4.5  3.1 mm),
width (8.0  4.2 mm), and area (26.6  31.0 mm2)
using the irrigated catheter system.
NEPI levels (Table 1) remained at baseline (16) (620
to 991 ng/g) for 7 of the treated arteries were and only
efﬁcaciously reduced (37 ng/g) in the treated RA with
maximal ablation area (99.1 mm2), depth (9.1 mm),
and width (15.9 mm). Remarkably, although the
maximal ablation zone of the efﬁcacious treatment
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1082involved all 4 quadrants of the section closest to the
ostium, only 27.3% of nerves in this section resided in
or near the ablation zone and were affected
(Figures 2A and 2B). The sole ganglion in this section
was beyond the ablation zone and was unaffected. In
contrast, more distally from the aorta (w3.0 mm),
treatment ablated a smaller area (15.2 mm2)
extending #2.1 mm from the lumen, yet 100% of
nerves in this section were within or adjacent to the
ablation zone and were affected (Figures 2C and 2D).
Tyrosine hydroxylase immunostaining of these
(Figures 3A and 3B) and neighboring sections
conﬁrmed that the majority of nerves within the
periarterial region, including the majority of affected
nerves, contained notable, diffuse sympathetic com-
ponents. Calcitonin gene-related peptide immuno-
staining, indicative of sensory afferent innervation,
was sparse and multifocal in affected and unaffected
nerves, including within individual nerve bundles.
In the 7 arteries in which no efﬁcacy was observed,
maximal ablation areas (Table 1) were smaller (16.2 
10.9 mm2) and restricted to 1 to 2 quadrants at
maximal depths of 3.8  2.7 mm, so that no gangliaFIGURE 3 Histopathological Appearance of Ostial
Sympathetic Nerves
Magniﬁed views of an unaffected nerve from Figure 2A (A) and
an affected nerve from Figure 2C (B). Tyrosine hydroxylase im-
munostaining is strong and diffuse in the unaffected nerve (A)
but patchy and granular in the affected nerve (B), which also
exhibits hypercellularity and architectural disruption as part of
the degenerative and proliferative response to treatment.
thological Appearance of the Norepinephrine-Reducing Ostial
sections (A) directly at or (C) w3.0 mm away from the aorta with
y: ablation zone (black line), affected nerves (circled red), unaffected
, and unaffected ganglion (circled green). Standardized comparison is
ing morphometric tracings (A and C) onto nerve maps (B and D) with
men (2.5 mm diameter). Orientation is uniform: top ¼ ventral, left ¼
rcle sizes denote the measured sizes of nerves (red ¼ affected, blue ¼
glia (green ¼ unaffected).and fewer than 33% of the nerves at the ostium were
affected (Figures 4A to 4D). Although variable nerve
distribution precluded correlation of renal NEPI
levels with nerve effects at the section closest the
ostium, NEPI levels did exhibit a threshold depen-
dence on the percentage of affected nerves as calcu-
lated across arterial sections (Figure 5). The data
illustrate that nerve ablation in distinct arterial cross
sections has an additive effect on renal NEPI, and that
efﬁcacious reduction requires an above threshold
nerve effect (between 20% to 63% of nerves, and most
likely around 50%). To contextualize these ﬁndings,
we evaluated innervation patterns at 3 distinct
distances from the aorta across all arteries (n ¼ 24).
ANATOMY OF PORCINE RA OSTIUM. Nerves and
ganglia were located closer to the lumen with
increasing distance from the aorta. At the aorta
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FIGURE 5 Threshold to Biomarker Effect
Norepinephrine (NEPI) levels (diamonds) dependence on the
percentage of affected nerves in affected arterial sections. A ﬁt
of Equation 1 (red line, R2 ¼ 0.85) estimates the threshold as
50.3% affected nerves.
FIGURE 4 Nonefﬁcacious Ostial Ablations
Maximal ablation zones along with nerve and ganglia positions
and sizes at the same distance from the aorta (w0.3 mm) are
depicted for treatments with norepinephrine levels as follows:
893 ng/g (A), 932 ng/g (B), and 620 ng/g (C). Circle sizes and
other ﬁgure details as described in Figure 2.
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1083(Figure 6A), nerves were localized (i.e., displayed fre-
quency >5%) at radial depths of 2 to 12 mm (median
6.3 mm). At a distance of w3.0 mm from the aorta
(Figure 6B), nerves were localized at radial depths of
2 to 8 mm (median 4.1 mm), whereas at a distance of
w6.0 mm (Figure 6C) nerves localized to radial depths
of 1 to 5 mm (median 2.0 mm). These differences were
statistically signiﬁcant (p < 0.001) and implied that
75% of nerves were located within 9.3, 6.3, and
3.4 mm of the lumen at the aorta and 3.0, and 6.0 mm
into the RA. Ganglion distributions displayed a
similar but less pronounced trend, with 75% located
within 10.8 mm from the lumen at the aorta versus
7.5 mm (p < 0.05) and 8.3 mm (p< 0.05) at distances of
3.0 and 6.0 mm from the aorta, respectively.
Circumferential distributions of nerves and
ganglia also varied with distance from the aorta, as
evidenced by quadrant-level composite maps. At the
aorta, nerves and ganglia were more abundant
in the superior-posterior and particularly the
superior-anterior (e.g., superior ostium) quadrants
(Figure 7A), but most were localized at >5 mm from
the lumen. At w3.0 mm from the aorta (Figure 7B),
nerves (but not ganglia) were more abundant in the
anterior and superior-posterior quadrants, and again
most were localized at >5 mm from the lumen. At
w6.0 mm from the aorta (Figure 7C), ganglia (but not
nerves) were more abundant in the superior quad-
rants at >5 mm from the lumen.
Nerve size (Online Table) but not ganglion size
exhibited a statistically signiﬁcant (p < 0.001)
dependence on distance from the aorta. Average
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FIGURE 6 The Radial Distributions of Nerves and Ganglia Become More
Diffuse Closer to the Ostium
Histograms of the relative abundances of nerves and ganglia are depicted at ostial
distances of 0.3 mm (A), 3.0 mm (B), and 6.0 mm (C). Data from Figures 7A to 7C.
Tzafriri et al. J A C C V O L . 6 4 , N O . 1 1 , 2 0 1 4
Anatomy Inﬂuences Efﬁcacy of Renal Ablation S E P T E M B E R 1 6 , 2 0 1 4 : 1 0 7 9 – 8 7
1084nerve size increased from 165 mm at the aorta to
185 mm at w3.0 mm and 216 mm at w6.0 mm.
DISCUSSION
Sympathetic nerve activity contributes to the devel-
opment and progression of hypertension and some
of its comorbidities (17). Catheter-based RDN can re-
duce sympathetic activity (18) and has been approved
in some countries for treatment of resistant hyper-
tension (19). However, pre-clinical data, which would
allow us to fully understand the physiology and
anatomy of the renal sympathetic nervous system
and to guide procedures, are incomplete, leading to
anecdotal treatment recommendations. One such
procedural recommendation is to intensively treat
the RA ostium (9,19), especially the superior part,
which is thought to be particularly rich in ganglia and
sympathetic nerves. Placement of single electrode
catheters in the proximal part of the renal arteries can
be challenging and may be unstable and without
sufﬁcient wall contact (20,21), raising the question
about whether patients really derive beneﬁt from
such attempts? Herein, for the ﬁrst time to our
knowledge, we provided quantitative data on nerve
and ganglia distribution near the ostium that can
help guide the decision as to preferential treatment
sites.
Although several trials have shown that RDN can
reduce blood pressure (1,5,6,22), the recent blinded,
sham-controlled SYMPLICITY HTN-3 trial failed to
reach its primary efﬁcacy endpoint, deﬁned as a sig-
niﬁcant difference in systolic blood pressure between
the RDN group and the sham-treated group (7). The
procedures were mostly performed using the
ﬁrst-generation single-electrode monopolar catheter
systems to deploy RF energy to the vessel wall. One
of the major limitations of the available techniques is
the absence of intraprocedural tests to assess proper
wall contact and effective destruction of the renal
sympathetic nerves (8). Indeed, it appears that RDN
only lowers blood pressure in certain patients but
not in all. Subsequent to the SYMPLICITY HTN trials,
nonresponse to RDN was deﬁned as systolic blood
pressure reduction of <10 mm Hg 6 months after
treatment. However, blood pressure response after
RDN varies, and in up to 50% of subjects, blood pres-
sure changes are minor or absent (23). Several causes
for clinical nonresponse have been proposed: inap-
propriate patient selection, changes in adherence
during follow-up, minor contribution of sympathetic
nerve activity to hypertension, and ineffective
procedures. The latter may beneﬁt from catheter
reﬁnements and scientiﬁcally sound treatment
FIGURE 7 Cross-Sectional Nerve and Ganglion Distributions
Vary With Distance From the Aorta
Composite polar coordinate distributions are depicted at
distances from the aorta: 0.3 mm (A), 3.0 mm (B), and 6.0 mm
(C). Nerve and ganglia are depicted by closed circles of varying
radii based on measured sizes. Red dashes depict the location
of an idealized lumen. Purple dashes depict the locus of points
that are 2.5 mm and 5.0 mm away from the lumen. Orientation:
top ¼ ventral, left ¼ cranial.
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1085recommendations. We were able to document for the
ﬁrst time a correlation between NEPI, the biomarker
for ablation effects, and the percentage of affected
nerves in treated arterial segments. NEPI levels
remained at baseline for treatments that affected
#20% of nerves in the treated segment, as it seems
that 50% of nerves must be ablated to achieve
half-maximal NEPI reduction.
The variable impact of RDN merits consideration
of variability in target anatomy. Nerve density is
higher in proximal segments of the renal arteries,
although with increasing distance from the aorta,
nerve, and ganglia they are localized closer to the
lumen. As the average ablation depth of available RF
RDN systems is w3 to 4 mm, our assessment of ostial
tissue sections suggests that this anatomic site may
be unfavorable for intravascular RDN, contrary to
widely-held beliefs. Our study suggests that ostial
ablations extending up to 5 mm from the lumen can
affect #38% of nerves, whereas a 5 mm ablation
applied $6 mm from the aorta can affect up to 85% of
nerves. The efﬁcacy of intravascular RDN within a
given RA segment, particularly by single electrodes, is
therefore dependent on the circumferential location
and depth from the luminal surface of sympathetic
nerves and ganglia (Central Illustration). Although our
data conﬁrmed that nerves and ganglia are more
abundant at the superior ostium, they also showCENTRAL ILLUSTRATION Threshold to Biomarker Effect
Renal norepinephrine levels exhibit a threshold dependence on the percentage of affected
nerves (red circles), namely those residing within or at the periphery of the ablation zone
(black line). Far from the ablation zones, nerves (blue circles) and ganglia (green circles)
are unaffected.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Sympathetic nerve activity contributes to hyperten-
sion and its comorbidities, but the response to
catheter-based RDN has been variable in studies
conducted to date.
TRANSLATIONAL OUTLOOK: More detailed
knowledge of RA innervation patterns derived from
animal models might be useful in guiding interven-
tions in patients with hypertension to yield more
consistent antihypertensive effects.
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1086that excess ablation targets were distributed >5 mm
from the lumen, and therefore, were beyond the
reach of typical ablations.
STUDY LIMITATIONS. Because the vasculorenal
anatomy of pigs is generally similar to that of humans,
pigs are considered the preferred animal model of
renal denervation (16), but caution is warranted in
translating our ﬁndings to humans as the renal arteries
in young, healthy swine may be different from the
renal arteries of long-standing hypertensive patients
with respect to calciﬁcation, compliance, length, and
tortuosity. However, Sakakura et al. (13) recently re-
ported similar trends in human RAs. Based on an
analysis of 20 human autopsy subjects (n ¼ 40 renal
arteries), they reported that nerves are more abundant
in the proximal versus distal segments (40/section vs
34/section, p ¼ 0.03) but also more distant from the
lumen (50th percentile: 2.84 vs. 1.81 mm; 75th
percentile: 4.67 vs. 3.24 mm). Although this trend is
similar to our own ﬁndings up to 6 mm from the aorta,
Sakakura et al. (13) observed statistically equivalent
nerve distributions in proximal and middle segments.
This difference in the sensitivity of nerve distribution
to the distance from the aorta speaks to the greater
resolution provided by our ﬁner segmentation along
the length of the animal artery and that arteries in the
pig are not alerted by concomitant long-standing
hypertension.
CONCLUSIONS
RDN therapies, which assume symmetric neural net-
works, run the real risk of missing nerves whenunitary lesions are imposed. This is especially true for
the renal ostium which, although an attractive target,
imposes signiﬁcant challenges. Ganglia and nerves
are more abundant at the renal ostium but are located
farther from the lumen and are present in all 4
quadrants, not just the superior aspect. Penetration
depths, which ablate along the length of the RA, are
ineffective at the ostium. As we move forward with
this emerging technology, we need to match treat-
ment strategies with increasing understanding of the
target anatomy.
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